NASDAQ$OFIX

Orthofix Medical Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Orthofix and SeaSpine's financial performance for the fourth quarter and full year of 2022 was reported.

Orthofix reported Q4 net sales of $122.2 million, a decrease of 2% year-over-year, while SeaSpine reported net sales of $63.4 million, a 14% increase year-over-year. Both companies highlighted growth in key segments and are now focused on integration following their merger on January 5, 2023.

  • Orthofix net sales decreased by 2% to $122.2 million, but remained flat on a constant currency basis.
  • Bone Growth Therapies net sales for Orthofix increased by approximately 3%.
  • SeaSpine net sales increased by 14% to $63.4 million.
  • U.S. Spinal Implants and Orthobiologics net sales for SeaSpine grew by 23% and 20%, respectively.

Headline financials

Total Revenue

$122M

Previous: $125M-2.3%
EPS (adj)

$0.19

Previous: $0.27-29.6%
Capital Expenditures

$5.21M

Previous: $6.23M-16.4%
Free Cash Flow

-$2.86M

Previous: $5.55M-151.4%
Net Income

-$7.06M

Previous: -$32.8M+78.5%
Operating Income

-$11M

Previous: -$9.35M-18.1%
Gross Profit

$89.2M

Previous: $91.8M-2.9%
Cash & Equivalents

$50.7M

Previous: $87.8M-42.3%
Total Assets

$459M

Previous: $477M-3.8%
Stock-Based Comp

$4.92M

Previous: $3.96M+24.2%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$122M

Q4 2022-2.3%vs Q4 2021
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

Orthofix · $109M total across 3 segments · Q4 2022

  • Bone Growth Therapies
    $51M+2.8%
  • Spinal Implants & Biologics
    $28.9M-7.4%
  • Global Limb Reconstruction
    $28.7M-1.8%

Forward guidance

The combined company expects net sales for the first quarter of 2023 to be between $166 million and $170 million, and full year net sales to be between $743 million and $753 million. These expectations are based on current foreign currency exchange rates and exclude the 2023 revenue results for SeaSpine for the four-day period prior to the closing of the merger.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro